靶向抑制CDK12/13在高级别胶质瘤中的体外治疗效果和作用分子机制探究

梅艳青, 韩雨洁, 翁文筠, 张蕾, 唐玉杰

In vitro therapeutic effects and molecular mechanisms of targeted inhibition of CDK12/13 in high-grade gliomas

MEI Yanqing, HAN Yujie, WENG Wenyun, ZHANG Lei, TANG Yujie

图3 CDK12/13抑制剂对DIPG和GBM体外生长的抑制作用 Note： A. Dosage-dependent cell viability curves of CDK12/13 inhibitor SR-4835 or THZ531-treated GBM or DIPG cell lines. B. Detection of proliferation and apoptosis of DIPG17 cells treated with DMSO or SR-4835 (0.1, 1 μmol/L) by flow cytometry. C. Detection of proliferation and apoptosis of SF188 cells treated with DMSO or SR-4835 (0.1, 1 μmol/L) by flow cytometry. D. Detection of proliferation and apoptosis of U251 cells treated with DMSO or SR-4835 (0.1, 1 μmol/L) by flow cytometry. Cell proliferation was detected by EdU-flow cytometry on 24 h and apoptosis was detected by Annexin V/PI-flow cytometry on 48 h.

Fig 3 Inhibitory effect of CDK12/13 inhibitors on the growth of DIPG and GBM in vitro